Print

Suven Life Sciences Ltd to Present at Alzheimer's Association International Conference (AAIC)  
7/12/2013 9:06:29 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HYDERABAD, INDIA (July 12, 2013) - Several exciting new results and data presentations from Suven’s portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at Alzheimer's Association International Conference(AAIC) being held in Boston, USA during July 13-18, 2013.

AAIC is the world's largest conference of its kind, bringing together researchers from around the world to report and discuss groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders.

Alzheimer’s disease is one of the scourges of modern day health care which is the largest and fastest growing unmet medical need and Suven is in the forefront of developing a drug for the treatment of this debilitating disease. Alzheimer's is a dementia that causes problems with memory, thinking and behavior. Alzheimer’s is not just a memory loss as everyone thinks but Alzheimer’s kills.

Suven has excellent portfolio of new molecules through four mechanisms of action using 5-HT6, 5-HT4, H3 and Neuronal Nicotinic acetylcholine receptors for the treatment of cognitive impairment in Alzheimer’s disease symptomatically but also possibly useful in reducing the disease progression. Suven scientists are presenting pre-clinical and clinical data on these molecule and other NCEs on cognitive impairment and memory related disorders.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease and Parkinson's disease in addition to clinical candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven please visit our Web site at http://www.suven.com

Safe Harbor Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Help employers find you! Check out all the jobs and post your resume.

//-->